Wolverine Trading
SMMT icon

Wolverine Trading’s Summit Therapeutics SMMT Stock Holding History

Wolverine Trading’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.76M Buy
130,300
+11,200
+9% +$272K ﹤0.01% 1896
2025
Q2 		$2.45M Buy
119,100
+42,800
+56% +$976K ﹤0.01% 1553
2025
Q1 		$1.55M Sell
76,300
-13,500
-15% -$271K ﹤0.01% 1843
2024
Q4 		$1.61M Sell
89,800
-47,800
-35% -$927K ﹤0.01% 2163
2024
Q3 		$2.87M Buy
137,600
+104,800
+320% +$1.47M ﹤0.01% 1432
2024
Q2 		$256K Buy
+32,800
New +$177K ﹤0.01% 3570

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Wolverine Trading's SMMT Position: Q2 2025 in Review

Wolverine Trading sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 14,431 shares — an estimated $329K sold.

Wolverine Trading first reported a position in SMMT in Q1 2023 and held it in 5 quarters. The position peaked at $1.48M in Q3 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Wolverine Trading reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 14,431 Summit Therapeutics shares in Q2 2025, an estimated $329K.
  • Wolverine Trading first reported a position in Summit Therapeutics in Q1 2023 and held it in 5 quarters.
  • Wolverine Trading's Summit Therapeutics position peaked at $1.48M in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.